logo

Astellas Pharma Inc. (ALPMY)



Trade ALPMY now with
  Date
  Headline
4/27/2022 2:53:51 AM Astellas Pharma FY EPS 103.03 Yen Vs 113.03 Yen Last Year
4/25/2022 2:03:03 AM University Of Tokyo, Astellas Enter Into Partnership For Co-creation Of New Medicines And Medical Solutions
3/7/2022 8:32:30 AM Astellas Announces Topline Results From Long-Term Phase 3 Safety Study Of Fezolinetant
12/17/2021 6:49:14 AM Astellas And Seagen Get Positive CHMP Opinion For PADCEV In Locally Advanced Or Metastatic Urothelial Cancer
12/1/2021 8:00:31 PM Astellas And Dyno Therapeutics To Develop AAV Gene Therapy Vectors For Skeletal And Cardiac Muscle
10/12/2021 8:02:51 AM Astellas Closes Enrollment In EV-103 Trial Cohort K Combining PADCEV With Pembrolizumab As Urothelial Cancer Treatment
9/27/2021 3:02:52 AM Astellas Pharma Says Japan's MHLW Approves PADCEV For Advanced Urothelial Cancer
9/22/2021 8:03:25 AM Astellas To Present Fezolinetant Findings From Phase 3 SKYLIGHT 2 Trial At North American Menopause Society Meeting
9/1/2021 2:02:52 AM Astellas Updates On ASPIRO Clinical Trial Of AT132 In Patients With X-linked Myotubular Myopathy
8/18/2021 7:07:06 AM Astellas Partners With LabCentral To Help Emerging Biotechs Accelerate Preclinical Scientific Research